Peggy M. Kostakou

Peggy M. Kostakou

Auto-generated profile, based on publicly available information

Peggy M. Kostakou

Department of Clinical Therapeutics, National and Kapodistrian University of Athens Medical School, Athens, Greece (Drs Delialis, Manifava, Konstantaki, Athanasopoulos, Zervas, Nastatos, Mavraganis, Dimopoulou, Kokkinidou, Rachiotis, Angelidakis, Papoutsis, Kostakou, Georgiopoulos, and Stamatelopoulos)

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2018 in Heart Failure Reviews
Verified
Journal Article
Closed access
PDF file
PKPeggy M. Kostakou
Peggy M. Kostakou
NKNikos T. Kouris
Nikos T. Kouris
VKVassilios S. Kostopoulos
Vassilios S. Kostopoulos
DDDimitrios S. Damaskos
Dimitrios S. Damaskos
COChristoforos D. Olympios
Christoforos D. Olympios

1 May 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
PKPeggy M. Kostakou
Peggy M. Kostakou
VKVassilis S. Kostopoulos
Vassilis S. Kostopoulos
ETElsi S. Tryfou
Elsi S. Tryfou
VGVassilis D. Giannaris
Vassilis D. Giannaris
IRIoannis E. Rodis
Ioannis E. Rodis
NKNikos T. Kouris
Nikos T. Kouris

26 June 2009 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
KAKatherine Anagnostopoulou
Katherine Anagnostopoulou
GKGenovefa D Kolovou
Genovefa D Kolovou
PKPeggy M Kostakou
Peggy M Kostakou
CMConstantinos Mihas
Constantinos Mihas
GHGeorgios Hatzigeorgiou
Georgios Hatzigeorgiou
DCDennis V Cokkinos
Dennis V Cokkinos
Background: This study assessed the gender-specific influence of the cholesteryl ester transfer protein (TaqIB, I405V) and lipoprotein lipase (S447X) polymorphisms on the response to an oral fat tolerance test in heterozygotes for familial hypercholesterolaemia. Methods: We selected and genotyped 80 men and postmenopausal women heterozygous for familial hypercholesterolaemia (main group) as well as 11 healthy control subjects. Patients were subgrouped based on their response to oral fat tolerance test. The oral fat tolerance test was defined as pathological when postprandial triglyceride concentration was higher than the highest triglyceride concentration observed in healthy subjects (220 mg/dl) at any time (2, 4, 6 or 8 h). Results: In the pathological subgroup, men had significantly higher incremental area under the curve after oral fat tolerance test than postmenopausal women. Furthermore, multivariate analysis revealed a gender association of TaqIB and I405V influence on postprandial lipaemia in this subgroup. Conclusion: In conclusion, it seems that gender and TaqIB polymorphism of the cholesteryl ester transfer protein gene were both associated with the distribution of triglyceride values after oral fat tolerance test, only in subjects with a pathological response to oral fat tolerance test. Specifically, men carrying the B2 allele of the TaqIB polymorphism showed a higher postprandial triglyceride peak and a delayed return to basal values compared with women carrying B2. However, further investigations in larger populations are required to replicate and confirm these findings.

11 March 2021 in Echocardiography
Verified
Journal Article
Closed access
PDF file
NKNikos T. Kouris
Nikos T. Kouris
VKVassilis S. Kostopoulos
Vassilis S. Kostopoulos
GPGeorgia A. Psarrou
Georgia A. Psarrou
PKPeggy M. Kostakou
Peggy M. Kostakou
CTChara Tzavara
Chara Tzavara
COChristoforos D. Olympios
Christoforos D. Olympios

1 January 2010 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
PKPeggy Kostakou
Peggy Kostakou
GKGenovefa D Kolovou
Genovefa D Kolovou
KAKatherine Anagnostopoulou
Katherine Anagnostopoulou
TTTheodor Theodoridis
Theodor Theodoridis
VGVassiliki Galea
Vassiliki Galea
DCDennis V Cokkinos
Dennis V Cokkinos

Verified
Journal Article
Open access
PDF file
Nikolaos-Iason TepetesNikolaos-Iason Tepetes
Nikolaos-Iason Tepetes
Christos KourekChristos Kourek
Christos Kourek
APAdamantia Papamichail
Adamantia Papamichail
Andrew XanthopoulosAndrew Xanthopoulos
Andrew Xanthopoulos
PKPeggy Kostakou
Peggy Kostakou
Alexandros BriasoulisAlexandros Briasoulis
Alexandros Briasoulis
Advanced heart failure (AHF) represents the terminal stage of heart failure (HF), characterized by persistent symptoms and functional limitations despite optimal guideline-directed medical therapy (GDMT). This review explores the clinical definition, pathophysiology, and therapeutic approaches for AHF. Characterized by severe symptoms, New York Heart Association (NYHA) class III-IV, significant cardiac dysfunction, and frequent hospitalizations, AHF presents substantial challenges in prognosis and management. Pathophysiological mechanisms include neurohormonal activation, ventricular remodeling, and systemic inflammation, leading to reduced cardiac output and organ dysfunction. Therapeutic strategies for AHF involve a multidisciplinary approach, including pharmacological treatments, device-based interventions like ventricular assisted devices, and advanced options such as heart transplantation. Despite progress, AHF management faces limitations, including disparities in access to care and the need for personalized approaches. Novel therapies, artificial intelligence, and remote monitoring technologies offer future opportunities to improve outcomes. Palliative care, which focuses on symptom relief and quality of life, remains crucial for patients ineligible for invasive interventions. Early identification and timely intervention are pivotal for enhancing survival and functional outcomes in this vulnerable population. This review underscores the necessity of integrating innovative technologies, personalized medicine, and robust palliative strategies into AHF management to address its high morbidity and mortality.